Synopsis
Synopsis
0
KDMF
0
NDC API
0
EDQM
0
USP
0
JP
0
Others
0
Australia
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1,1'-hbcb
2. Avagard
3. Chlorhexamed
4. Chlorhexidine Bigluconate
5. Chlorhexidine Digluconate
6. Corsodyl Ici
7. Curasept Ads 220
8. Dyna-hex
9. Eludril
10. Gibitan
11. Hexidine
12. Hibiclens
13. Hibident
14. Hibiscrub
15. Hibisol
16. Hibitane
17. Peridex
18. Perio Chip
1. Chlorhexidine Digluconate
2. Hibiclens
3. 18472-51-0
4. Peridex
5. Dyna-hex
6. Bioscrub
7. Chlorhexidine D-digluconate
8. Exidine
9. Microderm
10. Periochip
11. Periogard
12. Unisept
13. Brian Care
14. Steri-stat
15. Cida-stat
16. Hibistat
17. Pharmaseal Scrub Care
18. Chg Scrub
19. Prevacare
20. Chlorhexidine Digluconate Solution
21. Chlorhexidine Di-d-gluconate
22. Mor84mud8e
23. Nsc-753971
24. Hibiscrub
25. Hibitane
26. 1,1'-hexamethylene Bis(5-(p-chlorophenyl)biguanide), Digluconate
27. 1,1'-hexamethylenebis(5-(p-chlorophenyl)biguanide) Di-d-gluconate
28. Bacticlens
29. Chlorhexamed
30. Kleersight
31. Corsodyl
32. Disteryl
33. Hibident
34. Hibidil
35. Orahexal
36. Plurexid
37. Septeal
38. Abacil
39. Fight Bac
40. Plac Out
41. Prevacare R
42. Arlacide G
43. Hibitane 5
44. 2,4,11,13-tetraazatetradecanediimidamide, N,n''-bis(4-chlorophenyl)-3,12-diimino-, Di-d-gluconate
45. Chlorhexidin Glukonatu
46. Peridex (antiseptic)
47. Bactoshield Chg 2%
48. Caswell No. 481g
49. Unii-mor84mud8e
50. Pwriochip
51. Chlorhexidin Glukonatu [czech]
52. 1,6-bis(n5-[p-chlorophenyl]-n1-biguanido)hexane
53. Phiso-med
54. Hibitane Gluconate
55. Hibiclens (tn)
56. Periogard (tn)
57. Drg-0091
58. Einecs 242-354-0
59. Peridex (tn)
60. Mfcd00083599
61. Chlohexidine Gluconate
62. Epa Pesticide Chemical Code 045504
63. Readyprep Chg
64. Chlorhexidine Gluconate [usan:usp:jan]
65. Ec 242-354-0
66. Schembl34468
67. 1,6-bis(5-(p-chlorophenyl)biguandino)hexane Digluconate
68. Chembl4297088
69. Dtxsid5034519
70. Chebi:28312
71. 1,1'-hexamethylenebis(5-(p-chlorophenyl)biguanide) Gluconate
72. 1,1'-hexamethylenebis(5-(p-chlorophenyl)biguanide)digluconate
73. Chx Plus Concentrate Premium Chlorhexidine Teat Dip Concentrate
74. Biguanide, 1,1'-hexamethylenebis(5-(p-chlorophenyl)-, Digluconate
75. Chlorhexidine Gluconate (jp17/usp)
76. Chlorhexidine Gluconate [jan]
77. Chlorhexidine Gluconate [usan]
78. Akos015896303
79. Akos025310696
80. Chlorhexidine Gluconate [mart.]
81. Chlorhexidine Gluconate [vandf]
82. Nsc 753971
83. Chlorhexidine D-digluconate [mi]
84. Chlorhexidine Digluconate [inci]
85. Chlorhexidine Gluconate [who-dd]
86. Gluconic Acid, Compd. With 1,1'-hexamethylene Bis(5-(p-chlorophenyl)biguanide) (2:1), D-
87. D-gluconic Acid, Compd. With N,n''-bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide (2:1)
88. D-gluconic Acid, Compound With N,n''-bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediamidine (2:1)
89. Chlorhexidine Gluconate [orange Book]
90. Chlorhexidine Gluconate [usp Impurity]
91. Avagard Component Chlorhexidine Gluconate
92. C08038
93. D00858
94. Chlorhexidine Digluconate Solution, 20% In H2o
95. Soluprep Component Chlorhexidine Gluconate
96. Chloraprep Component Chlorhexidine Gluconate
97. Chlorhexidine Gluconate Component Of Avagard
98. Chlorhexidine Digluconate, 20% W/v Aqueous Solution
99. Chlorhexidine Gluconate Component Of Soluprep
100. J-011837
101. Chlorhexidine Gluconate Component Of Chloraprep
102. Chlorhexidine Digluconate Solution [ep Monograph]
103. 1,1'-hexamethylenebis[5-(4-chlorophenyl)biguanide] Digluconate
104. Chlorhexidine Digluconate, Pharmaceutical Secondary Standard; Certified Reference Material
105. 1,1'-hexamethylenebis[5-(p-chlorophenyl)biguanide] (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoic Acid(1:2)
106. 1-(4-chlorophenyl)-3-[n-[6-[[n-[n-(4-chlorophenyl)carbamimidoyl]carbamimidoyl]amino]hexyl]carbamimidoyl]guanidine; (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoic Acid
107. 2,4,11,13-tetraazatetradecanediimidamide, N,n''-bis(4-chlorophenyl)-3,12-diimino-, Digluconate
108. 2,4,11,13-tetraazatetradecanediimidamide, N,n'-bis(4-chlorophenyl)-3,12-diimino-, Di-d-gluconate
109. D-gluconic Acid, Compd With N,n''-bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide (2:1)
110. D-gluconic Acid, Compd. With N,n''-bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecane Diimidamide (2:1)
111. D-gluconic Acid, Compd. With N1,n14-bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide (2:1)
112. N',n'''''-hexane-1,6-diylbis[n-(4-chlorophenyl)(imidodicarbonimidic Diamide)]--d-gluconic Acid (1/2)
| Molecular Weight | 897.8 g/mol |
|---|---|
| Molecular Formula | C34H54Cl2N10O14 |
| Hydrogen Bond Donor Count | 18 |
| Hydrogen Bond Acceptor Count | 16 |
| Rotatable Bond Count | 23 |
| Exact Mass | 896.3198018 g/mol |
| Monoisotopic Mass | 896.3198018 g/mol |
| Topological Polar Surface Area | 455 Ų |
| Heavy Atom Count | 60 |
| Formal Charge | 0 |
| Complexity | 819 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 8 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 2 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
| 1 of 2 | |
|---|---|
| Drug Name | Chlorhexidine gluconate |
| Drug Label | Chlorhexidine Gluconate is an oral rinse containing 0.12% chlorhexidine gluconate (1,11-hexamethylene bis[5-(p-chlorophenyl) biguanide] di-D-gluconate) in a base containing water, 11.6% alcohol, glycerin, PEG-40 sorbitan diisostearate, flavor, sodium... |
| Active Ingredient | Chlorhexidine gluconate |
| Dosage Form | Cloth; Solution; Sponge |
| Route | Dental; Topical |
| Strength | 0.12%; 2%; 4% |
| Market Status | Over the Counter; Prescription |
| Company | Lyne; Wockhardt; Sage Prods; Hi Tech Pharma; Teva; Xttrium; Becton Dickinson |
| 2 of 2 | |
|---|---|
| Drug Name | Chlorhexidine gluconate |
| Drug Label | Chlorhexidine Gluconate is an oral rinse containing 0.12% chlorhexidine gluconate (1,11-hexamethylene bis[5-(p-chlorophenyl) biguanide] di-D-gluconate) in a base containing water, 11.6% alcohol, glycerin, PEG-40 sorbitan diisostearate, flavor, sodium... |
| Active Ingredient | Chlorhexidine gluconate |
| Dosage Form | Cloth; Solution; Sponge |
| Route | Dental; Topical |
| Strength | 0.12%; 2%; 4% |
| Market Status | Over the Counter; Prescription |
| Company | Lyne; Wockhardt; Sage Prods; Hi Tech Pharma; Teva; Xttrium; Becton Dickinson |
Antiseptic; disinfectant. (Vet): antiseptic; disinfectant.
O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK: Royal Society of Chemistry, 2013., p. 371
Cleanser: As a surgical hand scrub, skin wound and general skin cleanser, health care personnel hand wash, and for preoperative skin preparation. Chlorhedine gluconate significantly reduces the number of microorganisms on the hands and forearms prior to surgery or patient care. /Chlorhexidine gluconate-topical/
Drug Facts and Comparisons 2013. Wolters Kluwer Health St. Louis, MO 2013, p. 3180
EXPL THER To determine if chlorhexidine can be used as an intervention to prolong the time to relapse of oral candidiasis. SUBJECTS AND METHODS: A double-blinded randomized clinical trial was performed in 75 HIV/AIDS subjects with oral candidiasis. Clotrimazole troche was prescribed, and the subjects were re-examined every 2 weeks until the lesions were completely eradicated. The subjects were then randomly divided into two groups; 0.12% chlorhexidine (n = 37, aged 22-52 years, mean 34 years) and 0.9% normal saline (n = 38, aged 22-55 years, mean 38 years). They were re-examined every 2 weeks until the next episode was observed. RESULTS: The time to recurrence of oral candidiasis between the chlorhexidine and the saline group was not statistically significant (P > 0.05). The following variables were significantly associated with the time of recurrence; frequency of antifungal therapy (P = 0.011), total lymphocyte (P = 0.017), alcohol consumption (P = 0.043), and candidiasis on gingiva (P = 0.048). The subjects with lower lymphocyte showed shorter oral candidiasis-free periods (P = 0.034). CONCLUSIONS: Chlorhexidine showed a small but not statistically significant effect in maintenance of oral candidiasis-free period. This lack of significance may be due to the small sample size. Further study should be performed to better assess the size of the effect, or to confirm our findings.
PMID:18627504 Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253386 Nittayananta W et al; Oral Dis. (7): 665-70 (2008)
/EXPTL Therapy:/ Rats were injected with 10 mg/kg azoxymethane sc weekly for 12 weeks to induce colorectal cancers. At 20 weeks, subtotal colectomies were performed on rats with colorectal tumors and without peritoneal implants or liver metastases. At the time of surgery, a cut portion of the tumor was placed in the abdomen for 30 minutes; the rats then randomly received peritoneal irrigation with chlorhexidine, or sterile water (control). Eight weeks postoperatively a necropsy was performed. At that time, obvious and suspected recurrences and the anastomotic area were sampled for histologic evaluation. Significant differences were seen with chlorhexidine vs. water for gross tumor (P=0.05) and microscopic tumor (P<0.05).
Stuntz M et al; Dis Colon Rectum 40 (9): 1058-8 (1997)
For external use only: For external use only. Keep out of eyes, ears, and mouth. Chlorhexidine gluconate should not be used as a preoperative skin preparation of the face or head. Misuse of products containing chlorhexidine gluconate has been reported to cause serious and permanent eye injury when it has been permitted to enter and remain in the eye during surgical procedures. If chlohexidine gluconate should contact these areas, rinse out promptly and thoroughly with cold water. Avoid contact with neninges. Do not use in genital area. /Chlorhexidine gluconate-topical/
Drug Facts and Comparisons 2013. Wolters Kluwer Health St. Louis, MO 2013, p. 3180
Sensitivity: Chlorhexidine gluconate should not be used by persons who have a sensitivity to it or its components.
Drug Facts and Comparisons 2013. Wolters Kluwer Health St. Louis, MO 2013, p. 3180
Hypersensitivity reactions: Irritation, sensitization, and generalized allergic reactions have been reported with chlorhexidine-containing products, especially in the genital areas. If adverse reactions occur and last more than 72 hr, discontinue use immediately and, if severe, contact a health care provider.
Drug Facts and Comparisons 2013. Wolters Kluwer Health St. Louis, MO 2013, p. 3180
Deafness: Chlorhexidine gluconate has been reported to cause deafness when instilled in the middle ear through perforate ear drums. /Chlorhexidine gluconate-topical/
Drug Facts and Comparisons 2013. Wolters Kluwer Health St. Louis, MO 2013, p. 3180
For more Drug Warnings (Complete) data for CHLORHEXIDINE (8 total), please visit the HSDB record page.
Anti-Infective Agents, Local
Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. (See all compounds classified as Anti-Infective Agents, Local.)
Dermatologic Agents
Drugs used to treat or prevent skin disorders or for the routine care of skin. (See all compounds classified as Dermatologic Agents.)
34 newborn infants who had been bathed in a standard manner with Hibiscrub were studied to find out whether it was absorbed percutaneously. Low levels of chlorhexidine were found in the blood of all 10 babies sampled by heel prick, and 5 of 24 from whom venous blood was taken. /Chlorhexidine gluconate/
PMID:475414 Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1545570 Cowen J et al; Arch Dis Child 54 (5): 379-83 (1979)
Percutaneous absorption of the antimicrobial agent chlorhexidine (labelled with carbon-14) was studied in rats. Less than 5% of the topically applied chlorhexidine was absorbed during a 5-day period. Excretion of absorbed radioactivity occurred mainly in the feces.
Chow CP, et al; Toxicol Lett 1(4): 213-16 (1978)
The percutaneous absorption of chlorhexidine gluconate (chlorhexidine digluconate; Hibitane) through hairless rat skin with or without stratum corneum was studied. For tests carried out on whole skin, storage in cutaneous structures after 48 hr was more important than diffusion; the reverse was observed for stripped skin. When the skin was stripped, the amount absorbed was multiplied by approximately 100, and the amount stored in skin by approximately 10. The difference in chlorhexidine diffusion observed between whole and stripped skin was related to the physicochemical characteristics of chlorhexidine. /Chlorhexidine gluconate/
Lafforque C et al; Int J Pharm 147: 243-6 (1997)
To evaluate the elimination kinetics of chlorhexidine in milk when used as an intramammary infusion to stop lactation in cows. ... The study was performed in 2 phases. Three cows were studied in each phase. All cows were treated with chlorhexidine suspension by infusion into a mastitic mammary gland quarter after 2 milkings 24 hours apart. Foremilk samples (100 mL) were collected from treated and untreated (controls) mammary gland quarters of each cow. Chlorhexidine was extracted from raw milk, and residue concentrations were quantified by use of high-performance liquid chromatography. Foremilk samples from days 2, 5, and 8 were analyzed in phase I, and samples from time 0 and days 3, 7, 14, 21, 28, 35, and 42 were analyzed in phase II. In phases I and II, there was no quantifiable transference of chlorhexidine to milk in untreated mammary gland quarters. Measurable chlorhexidine residues were found in milk from treated mammary gland quarters of 2 cows throughout the 42-day sample period in phase II. Estimated mean elimination half-life for chlorhexidine in milk was 11.5 days.
PMID:12830870 Middleton JR et al; J Am Vet Med Assoc 222 (12): 1746-9 (2003)
To evaluate the elimination kinetics of chlorhexidine in milk when used as an intramammary infusion to stop lactation in cows. ... The study was performed in 2 phases. Three cows were studied in each phase. All cows were treated with chlorhexidine suspension by infusion into a mastitic mammary gland quarter after 2 milkings 24 hours apart. Foremilk samples (100 mL) were collected from treated and untreated (controls) mammary gland quarters of each cow. Chlorhexidine was extracted from raw milk, and residue concentrations were quantified by use of high-performance liquid chromatography. Foremilk samples from days 2, 5, and 8 were analyzed in phase I, and samples from time 0 and days 3, 7, 14, 21, 28, 35, and 42 were analyzed in phase II. In phases I and II, there was no quantifiable transference of chlorhexidine to milk in untreated mammary gland quarters. Measurable chlorhexidine residues were found in milk from treated mammary gland quarters of 2 cows throughout the 42-day sample period in phase II. Estimated mean elimination half-life for chlorhexidine in milk was 11.5 days.
PMID:12830870 Middleton JR et al; J Am Vet Med Assoc 222 (12): 1746-9 (2003)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8379
Submission : 1990-01-19
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6987
Submission : 1987-05-19
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3003
Submission : 1977-08-12
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5930
Submission : 1985-05-22
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4012
Submission : 1980-12-15
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3986
Submission : 1980-11-18
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 1710
Submission : 1971-04-23
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7948
Submission : 1989-03-01
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2012-12-26
Pay. Date : 2012-11-27
DMF Number : 5782
Submission : 1985-04-08
Status : Active
Type : II
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7109
Submission : 1987-08-11
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - AEROSOL, METERED;TOPICAL - 4%
USFDA APPLICATION NUMBER - 19127
DOSAGE - SOLUTION;TOPICAL - 2%
USFDA APPLICATION NUMBER - 19422
DOSAGE - TABLET;DENTAL - 2.5MG
USFDA APPLICATION NUMBER - 20774
DOSAGE - SOLUTION;TOPICAL - 2%;70%
USFDA APPLICATION NUMBER - 208288
DOSAGE - SPONGE;TOPICAL - 2%;70% (1.5ML)
USFDA APPLICATION NUMBER - 20832
DOSAGE - SPONGE;TOPICAL - 2%;70% (10.5ML)
USFDA APPLICATION NUMBER - 20832
DOSAGE - SPONGE;TOPICAL - 2%;70% (1ML)
USFDA APPLICATION NUMBER - 20832
DOSAGE - SPONGE;TOPICAL - 2%;70% (26ML)
USFDA APPLICATION NUMBER - 20832
DOSAGE - SPONGE;TOPICAL - 2%;70% (3ML)
USFDA APPLICATION NUMBER - 20832
DOSAGE - SOLUTION;TOPICAL - 61%;1%
USFDA APPLICATION NUMBER - 21074
DOSAGE - SWAB;TOPICAL - 3.15%;70% (1.6ML)
USFDA APPLICATION NUMBER - 21524
DOSAGE - SWAB;TOPICAL - 3.15%;70% (1ML)
USFDA APPLICATION NUMBER - 21524
DOSAGE - SWAB;TOPICAL - 3.15%;70% (5.1ML)
USFDA APPLICATION NUMBER - 21524
DOSAGE - SWAB;TOPICAL - 2%;70% (0.67ML)
USFDA APPLICATION NUMBER - 21555
DOSAGE - SWAB;TOPICAL - 2%;70% (1.75ML)
USFDA APPLICATION NUMBER - 21555
DOSAGE - SWAB;TOPICAL - 2%;70% (5.25ML)
USFDA APPLICATION NUMBER - 21555
Related Excipient Companies
EUROAPI
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharm-RX Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Minbiotech
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kirsch Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ashland
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]BioSpectra
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CD Formulation
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Clariant
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Esteem Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Keval Exports
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lubrizol Life Science Health
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
Dosage Form : Tablet
Grade : Oral
Application : Thickeners and Stabilizers
Excipient Details : It provides solubility and viscosity stability on strong high viscosity.
Pharmacopoeia Ref : Monograph- USP/NF, JP/JPE
Technical Specs : Strong High Viscosity
Ingredient(s) : Carboxymethyl cellulose sodium
Dosage Form : Tablet
Grade : Oral
Application : Thickeners and Stabilizers
Excipient Details : It provides smooth solutions, based on uniform substitution with low viscosity.
Pharmacopoeia Ref : Monograph- USP/NF, JP/JPE
Technical Specs : Low Viscosity
Ingredient(s) : Carboxymethyl cellulose sodium
Dosage Form : Tablet
Grade : Oral
Application : Thickeners and Stabilizers
Excipient Details : It provides solubility and viscosity stability on medium viscosity.
Pharmacopoeia Ref : Monograph- USP/NF, JP/JPE
Technical Specs : Medium Viscosity
Ingredient(s) : Carboxymethyl cellulose sodium
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Bold Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nippon Fine Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nomisma Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Welltone Material Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ulanqab Kema New Material
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Valens Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Zhejiang Huakang Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Topical
Thickeners and Stabilizers
Parenteral
Solubilizers
Coating Systems & Additives
Fillers, Diluents & Binders
Film Formers & Plasticizers
Rheology Modifiers
Surfactant & Foaming Agents
Controlled & Modified Release
Taste Masking
Emulsifying Agents
Empty Capsules
Co-Processed Excipients
Direct Compression
Chewable & Orodispersible Aids
Lubricants & Glidants
API Stability Enhancers
Granulation
Disintegrants & Superdisintegrants
Soft Gelatin
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
53
PharmaCompass offers a list of Chlorhexidine Gluconate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Chlorhexidine Gluconate manufacturer or Chlorhexidine Gluconate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Chlorhexidine Gluconate manufacturer or Chlorhexidine Gluconate supplier.
PharmaCompass also assists you with knowing the Chlorhexidine Gluconate API Price utilized in the formulation of products. Chlorhexidine Gluconate API Price is not always fixed or binding as the Chlorhexidine Gluconate Price is obtained through a variety of data sources. The Chlorhexidine Gluconate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A BIOSCRUB manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of BIOSCRUB, including repackagers and relabelers. The FDA regulates BIOSCRUB manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. BIOSCRUB API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of BIOSCRUB manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A BIOSCRUB supplier is an individual or a company that provides BIOSCRUB active pharmaceutical ingredient (API) or BIOSCRUB finished formulations upon request. The BIOSCRUB suppliers may include BIOSCRUB API manufacturers, exporters, distributors and traders.
click here to find a list of BIOSCRUB suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A BIOSCRUB DMF (Drug Master File) is a document detailing the whole manufacturing process of BIOSCRUB active pharmaceutical ingredient (API) in detail. Different forms of BIOSCRUB DMFs exist exist since differing nations have different regulations, such as BIOSCRUB USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A BIOSCRUB DMF submitted to regulatory agencies in the US is known as a USDMF. BIOSCRUB USDMF includes data on BIOSCRUB's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The BIOSCRUB USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of BIOSCRUB suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The BIOSCRUB Drug Master File in Japan (BIOSCRUB JDMF) empowers BIOSCRUB API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the BIOSCRUB JDMF during the approval evaluation for pharmaceutical products. At the time of BIOSCRUB JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of BIOSCRUB suppliers with JDMF on PharmaCompass.
A BIOSCRUB CEP of the European Pharmacopoeia monograph is often referred to as a BIOSCRUB Certificate of Suitability (COS). The purpose of a BIOSCRUB CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of BIOSCRUB EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of BIOSCRUB to their clients by showing that a BIOSCRUB CEP has been issued for it. The manufacturer submits a BIOSCRUB CEP (COS) as part of the market authorization procedure, and it takes on the role of a BIOSCRUB CEP holder for the record. Additionally, the data presented in the BIOSCRUB CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the BIOSCRUB DMF.
A BIOSCRUB CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. BIOSCRUB CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of BIOSCRUB suppliers with CEP (COS) on PharmaCompass.
A BIOSCRUB written confirmation (BIOSCRUB WC) is an official document issued by a regulatory agency to a BIOSCRUB manufacturer, verifying that the manufacturing facility of a BIOSCRUB active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting BIOSCRUB APIs or BIOSCRUB finished pharmaceutical products to another nation, regulatory agencies frequently require a BIOSCRUB WC (written confirmation) as part of the regulatory process.
click here to find a list of BIOSCRUB suppliers with Written Confirmation (WC) on PharmaCompass.
BIOSCRUB Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of BIOSCRUB GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right BIOSCRUB GMP manufacturer or BIOSCRUB GMP API supplier for your needs.
A BIOSCRUB CoA (Certificate of Analysis) is a formal document that attests to BIOSCRUB's compliance with BIOSCRUB specifications and serves as a tool for batch-level quality control.
BIOSCRUB CoA mostly includes findings from lab analyses of a specific batch. For each BIOSCRUB CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
BIOSCRUB may be tested according to a variety of international standards, such as European Pharmacopoeia (BIOSCRUB EP), BIOSCRUB JP (Japanese Pharmacopeia) and the US Pharmacopoeia (BIOSCRUB USP).
